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OBJECTIVE—The impact of the diabetes risk gene transcrip-
tion factor 7-like 2 (TCF7L2) on body weight is unclear. As
TCF7L2 is expressed in adipose tissue and involved in Wnt-
dependent regulation of adipogenesis, we studied the impact of
TCF7L2 variants on body composition and weight loss during
lifestyle intervention.
RESEARCH DESIGN AND METHODS—We genotyped 309
German subjects at increased risk for type 2 diabetes for single
nucleotide polymorphisms (SNPs) rs7903146, rs12255372,
rs11196205, and rs7895340 in TCF7L2 and performed oral glu-
cose tolerance tests before and after a 9-month lifestyle interven-
tion. Fat distribution was quantiﬁed using whole-body magnetic
resonance imaging/spectroscopy in a subgroup of 210 subjects.
RESULTS—After adjustment for confounding variables, we
observed a negative impact of the type 2 diabetes allele of SNP
rs7903146 on change in BMI (P  0.0034) and on changes in
nonvisceral (P  0.0032) and visceral fat (P  0.0165) during
lifestyle intervention. An association of rs7903146 with lifestyle
intervention-induced changes in insulin secretion, glucose con-
centrations, liver fat, or insulin sensitivity were not detected (all
P  0.2). Essentially the same results were obtained with SNP
rs1255372. In contrast, we found no effects of SNPs rs11196205
and rs7895340 on change in BMI (all P  0.5).
CONCLUSIONS—Our data reveal that diabetes-associated al-
leles of TCF7L2 are associated with less weight loss in response
to lifestyle intervention. Thus, diabetes-associated TCF7L2 gene
variation predicts the success of lifestyle intervention in terms of
weight loss and determines individual susceptibility toward
environmental factors. Diabetes 59:747–750, 2010
V
ariation in the transcription factor 7-like two
(TCF7L2) gene strongly determines the risk of type
2 diabetes (1) mainly via what is believed to be its
effects on -cell function, and the insulin secretion
deﬁcit of carriers of the diabetes risk alleles (2) may be
explained at least in part by incretin resistance (3,4).
The association of TCF7L2 with weight-related traits and
body fat in humans is unclear. Conﬂicting data are reported
on the issue of whether there is an inﬂuence of TCF7L2
variants on insulin resistance (5–7) or liver fat (8), and a
modulation of BMI (9,10) and obesity was postulated (11).
Helgason et al. (12) deﬁned two haplotypes, HapBtype 2 diabetes
(rs7903146 efﬁciently tags HapB in all HapMap groups),
which is mainly associated with type 2 diabetes, and HapA
(rs7924080 efﬁciently tags HapA in all HapMap groups),
which shows a suggestive association with BMI and altered
concentrations of hunger-satiety hormones.
A role of TCF7L2 in adipocyte differentiation is hypoth-
esized for the following reasons: 1) TCF7L2 is expressed
in subcutaneous and visceral adipose tissue (11,13,14),
and a decrease in TCF7L2 expression in adipose tissue
could be demonstrated during caloric restriction (11); 2)
TCF7L2 is part of the Wnt signaling cascade, and Wnt
signaling inhibits adipogenesis (15–17); and 3) a polymor-
phism in the Wnt receptor LRP6 is associated with obesity,
the metabolic syndrome, and bone loss (18).
In this study, we investigated whether TCF7L2 variants,
ﬁrst, are associated with body fat composition and ectopic
lipid storage in our cross-sectional setting or, second,
interfere with changes in body composition or weight loss
during lifestyle intervention. To this end, we used a
whole-body magnetic resonance imaging (MRI) approach
enabling precise quantiﬁcation of body fat stores and
magnetic resonance spectroscopy (MRS) to measure ec-
topic fat deposition in the liver. In our analyses, we
focused on single nucleotide polymorphisms (SNPs)
rs7903146 and rs1255372, which have yielded the best
association with type 2 diabetes across multiple Caucasian
populations and tag haplotype HapBtype 2 diabetes (1–3). In
addition, we also investigated SNPs rs1196205 and rs7895340,
which were available in our cohort, are in near-complete
linkage with SNP rs7924080 (both r
2  0.89, HapMap data),
and therefore efﬁciently tag haplotype HapA (12).
RESEARCH DESIGN AND METHODS
We studied 309 nondiabetic German Caucasian subjects who participated in
the ongoing Tuebingen Lifestyle Intervention Program (TULIP) (19). The
subjects were at increased risk for type 2 diabetes (20). Most of these subjects
(70%) had a family history of diabetes. About 13% of the study subjects were
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diabetes.diabetesjournals.org DIABETES, VOL. 59, MARCH 2010 747related to each other. Oral glucose tolerance tests (OGTTs) revealed that 60%
of the nondiabetic participants had normal glucose tolerance, 13% had
impaired fasting glycemia, 14% had impaired glucose tolerance, and 13% had
both impaired fasting glycemia and impaired glucose tolerance.
OGTT. After an overnight fast, subjects ingested a solution containing 75-g
glucose at 08:00 h. Plasma glucose, insulin, and C-peptide concentrations were
determined at 0, 30, 60, 90, and 120 min thereafter.
Body composition. Total body fat was measured by bioelectrical impedance
(BIA-101; RJL Systems, Detroit, MI). In a subgroup of 210 subjects, an exact
quantiﬁcation of fat distribution was performed by MRI and MRS. Magnetic
resonance examinations were performed on a 1.5-T whole-body imager
(Magnetom Sonata; Siemens Medical Solutions, Erlangen, Germany). A whole-
body imaging protocol was applied for recording a set of 90–120 parallel
transverse slices. Slice thickness was 10 mm for the entire body. T1-weighted
contrast was applied, allowing semiautomatic quantitative assessment of fatty
tissue and other tissue types in each cross-section. MRI-derived visceral,
nonvisceral, and total fat mass are given in kilograms. Hepatic fat content
was determined by localized stimulated echo acquisition mode (STEAM)
1H-magnetic resonance spectroscopy (repetition time [TR]  4 s, echo time
[TE]  10 ms; 32 scans). The lipid content was quantitatively assessed by
analyzing the signal integral using the liver water signal integral as an internal
reference. MRS-derived hepatic fat is given in percent of water signal (21).
Lifestyle intervention. TULIP consists of exercise and dietary intervention
for 2 years, which was adopted from the intervention used in the Finnish
Diabetes Prevention Study (DPS) (10) and was previously reported (19). Since
this is an ongoing project and most data are available for the baseline and
9-month visit, we analyzed these data in the present study. The participants
aimed at a weight loss of at least 5%, a reduction of caloric intake from fat to
30% and an increase of ﬁber intake to at least 15 g/1,000 kcal. Individuals
were asked to perform at least3ho fmoderate exercise per week, which was
monitored using a heart rate monitor (Polar, Bu ¨ttelborn, Germany). All
individuals had up to 10 sessions with a dietitian during the 9 months.
Informed written consent was obtained from all participants, and the local
ethics committee approved the protocol.
Genotyping. DNA from whole blood was isolated using a commercial DNA
isolation kit (NucleoSpin; Macherey & Nagel, Du ¨ren, Germany). Genotyping
was performed using the TaqMan assay (Applied Biosystems, Forster City,
CA). The TaqMan genotyping reaction was ampliﬁed on a GeneAmp PCR
system 7000, and ﬂuorescence was detected on an ABI PRISM 7000 sequence
detector (Applied Biosystems). The genotyping success rates were 99.9% for
SNP rs7903146, 99.6% for SNP rs12255372, 99.1% for rs11196205, and 98.9% for
rs7895340. The genotypes were veriﬁed in 50 randomly selected subjects by
bidirectional sequencing, and both methods yielded 100% identical results.
Analytical procedures. Plasma insulin and C-peptide levels were determined
with a commercial chemiluminescence system (ADVIA Centaur; Siemens
Medical Solutions, Fernwald, Germany). Blood glucose was measured using a
bedside glucose analyzer and the glucose oxidase method. (Yellow Springs
Instruments, Yellow Springs, OH).
Calculations. The area under the curve (AUC) of glucose and C-peptide
during the OGTT was calculated according to the trapezoid method. Insulin
sensitivity during the OGTT was estimated according to the formula: 10,000/
(fasting glucose  fasting insulin  mean glucose [OGTT]  mean insulin
[OGTT])
1/2.
Statistical analyses. Unless otherwise stated, data are given as means  SD.
Data that were not normally distributed were logarithmically transformed
prior to statistical analysis. Hardy-Weinberg equilibrium was tested using the

2 test. Differences in parameters between genotypes were tested using
multivariate linear regression analysis. Differences with a P value 0.05 were
considered statistically signiﬁcant. The JMP 7.0 (SAS Institute, Cary, NC)
statistical software package was used.
Power calculation. The study was sufﬁciently powered (1 	  0.93) to
detect effect sizes as small as SD/5 in the overall cohort for change in BMI.
RESULTS
The observed minor allele frequency for SNP rs7903146
was 34%, for rs12255372 it was 29%, for rs11196205 it was
48%, and for rs7895340 it was 46%. All SNPs were in
Hardy-Weinberg equilibrium (P  0.4).
All data were adjusted for sex and age. Glucose concen-
trations, insulin secretion, and insulin sensitivity derived
from the OGTT were additionally adjusted for BMI. The
effect of the lifestyle intervention on glucose metabolism,
body composition, and weight loss was reported previ-
ously (19). Subject characteristics and effect of lifestyle
intervention are presented in Table 1.
In the cross-sectional setting, we found no association
of the type 2 diabetes risk SNP rs7903146 with insulin
sensitivity, BMI, bioimpedance-derived total body fat, vis-
ceral fat mass, nonvisceral fat mass, or liver fat (all P 
0.2) (Table 2). However, we observed a trend for lower
insulin secretion as measured by AUCC-Peptide/AUCGlucose
(P  0.07) and higher 120-min glucose (P  0.1) in type 2
diabetes risk allele carriers (Table 2).
During lifestyle intervention, the risk allele carriers
displayed lower reduction in BMI (P  0.0108) and total
body fat (Pdom  0.0155; Padd  0.07) (Table 2). SNP
rs7903146 explained 2.6% of the variation in the interven-
tion-induced change of BMI. The variant was not associ-
ated with changes in fasting or 120-min glucose, insulin
sensitivity, liver fat, or insulin secretion (all P  0.09).
Because of the known effect of the variant on insulin
secretion, we additionally adjusted the effect on change in
BMI for insulin secretion and 120-min glucose. This how-
ever did not alter the results.
In the MRI/MRS cohort, we observed in the risk allele
carriers a lower reduction in nonvisceral (Pdom  0.0022;
Padd  0.06) and visceral fat mass (Pdom  0.0165; Padd 
0.06) (Table 2). As adjustment for sex and age does not
completely account for sex- and age-speciﬁc interaction
effects of rs7903146 on body composition and weight loss,
we performed separate analyses for male and female and
old and young (separated by the median) study partici-
pants (supplemental Tables 1 and 2, available in an on-
line appendix at http://diabetes.diabetesjournals.org/cgi/
content/full/db09-1050/DC1). After stratiﬁcation for sex,
most of the associations observed in the overall cohort
were also seen in the subgroups, and no clear sex effects
TABLE 1
Anthropometric and metabolic parameters at baseline and changes during lifestyle intervention
Mean  SD Range 
Tfollow up 	 Tbaseline Mean  SD P
Age (years) 46  11 18–69
BMI (kg/m
2) 30.1  5.6 19.4–51.0 
BMI 	0.9  1.5 0.0001
Total body fat (%) 33.0  8.6 9.8–58.3 
Total body fat 	1.1  4.5 0.0001
Fasting glucose (mmol/l) 5.3  0.5 4.1–6.5 
Fasting glucose 	0.1  0.5 0.0011
Glucose120-min (mmol/l) 7.0  1.6 3.6–11.1 
Glucose120-min 	0.3  1.6 0.0001
AUCC-Peptide/AUCGlucose (10
	9) 1,217  660 60–4,385 
AUCC-Peptide/AUCGlucose 	0.4  74 0.9
Insulin sensitivity, OGTT (AU) 12.8  6.9 2.6–32.5 
Insulin sensitivity 1.8  6.2 0.0001
Nonvisceral fat (kg)* 23.2  10 3.4–60.5 
Nonvisceral fat 	2.0  3.4 0.0001
Visceral fat (kg)* 3.0  1.8 0.3–10.1 
Visceral fat 	0.4  0.6 0.0001
Liver fat content (% of water signal)* 6.6  8.3 0.2–44.7 
Liver fat content 	2.1  5.9 0.0001
n (female/male)  194/115. Changes during lifestyle intervention were statistically analyzed by MANOVA. *MRI/MRS subcohort.
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the associations of the overall cohort were only reﬂected
in the young subgroup.
To minimize the chance of statistical type 1 errors, we
additionally analyzed SNP rs12255372, which is in incom-
plete linkage disequilibrium with rs7903146 (r
2  0.77,
HapMap data). Essentially the same results were obtained
with rs12255372 (supplemental Table 3).
In contrast, SNPs rs11196205 and rs7895340 (tagging
haplotype HapA) were not associated with body composi-
tion cross-sectionally or with weight loss during lifestyle
intervention (all P  0.5) (supplemental Tables 4 and 5).
DISCUSSION
In the present study, we found in a population at risk for
type 2 diabetes that risk variants for type 2 diabetes of the
TCF7L2 gene (rs7903146, rs12255372) inﬂuence lifestyle
intervention-induced changes in BMI, total fat, and non-
visceral and visceral fat, while changes in insulin secre-
tion, insulin sensitivity, or blood glucose are unaffected.
Like our cross-sectional setting, most cross-sectional stud-
ies found no reliable association of variants in TCF7L2
gene with BMI (1,3,22). Nevertheless, Helgason et al. (12)
observed a moderately leaner phenotype in carriers of the
haplotype HapBtype 2 diabetes (0.44% lower BMI per copy).
The ﬁnding of a leaner phenotype is conﬁrmed in the
cross-sectional analyses of the Diabetes Prevention Pro-
gram (DPP) and the DPS (9,10). The authors of the DPP
concluded that their ﬁnding is unexpected and possibly
artiﬁcial (9). Subjects with lower insulin secretion, like the
TCF7L2 risk allele carriers, had a higher risk to develop
diabetes even though they were leaner. Therefore, there
may be a bias in the study population when enrolling only
subjects at risk for type 2 diabetes (9). Although the HapA
haplotype is reported to associate with BMI and altered
concentrations of hunger-satiety hormones (12), the
HapA-tagging SNPs tested in our cohort were not associ-
ated with weight loss in the longitudinal setting.
In the DPS as well as in the DPP, it was shown that the
diabetogenic effect of the SNPs rs7903146 and rs12255372
in TCF7L2 is mitigated by lifestyle intervention (9,10).
Changes in BMI and fat depots though were not reported
in the DPS and the DPP; therefore, we cannot draw
conclusions as to how changes in body weight inﬂuence
the outcome in these studies. However, it may be specu-
lated that smaller reductions in BMI and body fat due to
the risk allele may not necessarily inﬂuence type 2 diabe-
tes incidence, at least within the 3- to 4-year observation
period.
We currently have no explanation for the conﬂicting
ﬁndings with regard to the phenotype of TCF7L2 SNP
carriers in cross-sectional settings (9,10,12) versus our
longitudinal setting. In the present study, the intervention
was applied to all individuals so that each individual
served as his/her own historic control subject. This ap-
proach may explain the different ﬁndings of studies that
are fully randomized.
The effects of TCF7L2 on body fat found in this study
need replication in other larger cohorts and longer-term
lifestyle intervention studies to verify their clinical rele-
vance. These studies should include a control group
without weight loss and subjects not at high risk for
diabetes. In addition, studies at the molecular level should
also be undertaken to identify the possible mechanisms of
how TCF7L2 inﬂuences body fat change.
In conclusion, we show that diabetes-associated varia-
tion in TCF7L2 inﬂuences changes in BMI and body fat
and thus predicts the success of lifestyle intervention in
terms of weight loss. Therefore, TCF7L2 represents a gene
that inﬂuences individual susceptibility toward environ-
mental factors. The mechanisms of how the variants
interact with environmental factors to inﬂuence BMI are
not understood and need further investigation.
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TABLE 2
Associations of TCF7L2 SNP rs7903146 with anthropometric and metabolic parameters in the cross-sectional setting and with
changes in these parameters during lifestyle intervention by genotype
CC XT P1 P2C C X T P1 P2
n (female/male) 148 (95/53) 161 (99/62) —
Age (years) 46  10 47  12 —
BMI (kg/m
2) 30.3  5.5 30.0  5.8 0.5 0.7 
BMI 	1.2  1.6 	0.7  1.5 0.0034 0.0108
Total body fat (%) 33.7  8.5 32.5  8.7 0.3 0.3 
Total body fat 	1.7  4.5 	0.5  4.3 0.0155 0.07
Fasting glucose (mmol/l) 5.3  0.5 5.3  0.5 0.95 0.9 
Fasting glucose 	0.1  0.4 0.0  0.4 0.2 0.1
Glucose120-min (mmol/l) 6.8  1.5 7.2  1.7 0.05 0.1 
Glucose120-min 	0.2  1.6 	0.4  1.5 0.4 0.8
AUCC-Peptide/AUCGlucose
(10
	9) 317  96 295  88 0.06 0.07 
AUCC-Peptide/AUCGlucose 	2.6  78 1.5  70 0.3 0.8
Insulin sensitivity,
OGTT (AU) 12.5  7.0 13.0  6.8 0.4 0.6 
Insulin sensitivity 2.2  6.0 1.5  6.4 0.6 0.5
Nonvisceral fat (kg)* 23.5  9.5 22.8  10.3 0.5 0.8 
Nonvisceral fat 	2.7  3.6 	1.3  2.9 0.0022 0.06
Visceral fat (kg)* 3.0  1.8 3.0  1.9 0.2 0.3 
Visceral fat 	0.5  0.6 	0.3  0.6 0.0165 0.06
Liver fat content (% of
water signal)* 7.6  9.3 5.7  7.0 0.3 0.2 
Liver fat content 	2.7  5.8 	1.5  5.9 0.09 0.2
Data are means  SD. BMI and total body fat were adjusted for sex and age. Glucose concentration, insulin secretion, and insulin sensitivity
were additionally adjusted for BMI. 
Tfollow up 	 Tbaseline. The change in the parameters was additionally adjusted for baseline values. The
change in glucose concentration, insulin secretion, and insulin sensitivity was adjusted for the change in BMI. Data were statistically analyzed
by multivariate linear regression analysis in the dominant inheritance model, P1, and the additive inheritance model, P2. Data in bold
represent statistical signiﬁcance. *MRI/MRS subcohort.
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